Germany: reliable data on MS incidence available from 2-year study:
This article was originally published in Clinica
The German population of multiple sclerosis sufferers is currently 120,000, with 2,500 new cases recorded every year. The economic costs are some euro500m ($585m) per year in direct hospital costs and a further euro3.5bn in social benefits and other costs. A study led by Dr Peter Flachenecker, of the university hospital of Wurzburg set out to log patients at five regional centres over a two-year period, ending in December 2003. Their documentation project covered some 3,400 patients during this period allowing them to calculate new incidence as being 3 per 100,000 of population (based on observations in Rostock and Wurzburg). Newly-diagnosed MS patients were on average 30 years old. The project also revealed that two-thirds of observed patients were female; a third had limited mobility; 7% were wheelchair-bound; 1.6% were bed-bound. The register has since grown to 10,000 cases, and neurologists hope the knowledge put into this developing database will help in the management and therapy of patients.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.